ST. CLOUD, Minn. — Microbiologics entered into the virology industry only a little more than one year ago, but the St. Cloud-based biomaterial manufacturer is already making a big impact in the world of viruses and vaccines.
Microbiologics acquired San Diego-based Virapur at the end of 2017, allowing the company to expand its research and development support services to vaccines and gene therapy.
"We've more than doubled the business in the first year that we've had it, so it's very exciting for us," Microbiologics CEO Brad Goskowicz told the St. Cloud Times of the acquisition. "In the past, we've always been on the quality side of the business. Now we're on the R&D side."
Founded in 1971, Microbiologics is the leading provider of ready-to-use microorganisms for quality control testing in clinical, pharmaceutical, food, water and educational industries. It sells products to thousands of microbiology labs all over the world and currently does business in about 140 countries.
Goskowicz joined the company in 2009 as chief marketing officer and became CEO in 2010 as part of a planned transition.
With its acquisition of Virapur, some of Microbiologic's biggest projects in the last year have been in conjunction with vaccine manufacturers that are working on a universal flu vaccine.
"That's kind of the holy grail," Goskowicz said. "It would protect you against all of them regardless of what strain develops every year."
Beyond its vaccine work, Virapur also does work in viral gene therapy research.
"Right now it's a small part of our business," Goskowicz said.
Goskowicz said the goal is to about double Microbiologics' business to be a $100 million company by 2025.
"It's a specialized area and it fits with our mission, which is this idea of biomaterials for a healthier, safer world," Goskowicz said. "This fits what was what we do, and it'll get us into this adjacent market that's very attractive to us."
An AP Member Exchange shared by the St. Cloud Times.